HOME >> BIOLOGY >> NEWS
New antimalarial combination confirms its potential use in treating drug-resistant malaria

Yaound, Cameroon, 15th November 2005 Clinical results demonstrating the potential benefits of treating Plasmodium falciparum malaria with a new artemisinin-based combination therapy (ACT), chlorproguanil hydrochloride-dapsone-artesunate (CDA)1, were announced today at the 4th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Cameroon. CDA is being developed to meet the urgent need for new malaria treatments for Africa where drug resistance is contributing to an escalating health crisis. Dr. Arata Kochi, Director of the WHO Roll Back Malaria (RBM) Department stated, "The effort to develop CDA responds to RBM's call for fixed-dose artemisinin containing combinations."

The phase II trial of CDA, involving adults and children with P. falciparum malaria, was designed to determine the optimum dose of artesunate in combination with LapdapTM (chlorproguanil/dapsone). Treatment with CDA, at three doses of artesunate (1, 2 and 4mg/kg) in adults and at two doses (2 and 4mg/kg) in children, led to faster time to reduce parasite levels in the blood by 90 percent when compared to treatment with Lapdap alone.1 Reductions in parasite viability and potential parasite reproductive ability in patients were also greater in those treated with CDA than Lapdap alone. All treatment doses of CDA were generally well tolerated, and the nature and incidence of adverse events were similar across treatment groups.1

"These results suggest that CDA could become a major weapon in the fight against drug-resistant malaria. Moving into phase III trials marks a key step in the development of this promising antimalarial," commented Dr. Chris Hentschel, CEO of MMV.

Phase III trials for CDA are planned across sub-Saharan Africa and will further study the safety and efficacy of treating P. falciparum malaria with CDA. One study will compare CDA against the only fixed-dose ACT currently available for the treatment of P. falciparum, artemether/lumefantrine, over a
'"/>


15-Nov-2005


Page: 1 2

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Research milestone brings goal closer of cheap antimalarial drug for developing world
3. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World
4. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
5. New study suggests promising drug combinations for sleeping sickness
6. Recombination protein dynamics observed with single monomer resolution
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New combination treatment induces regression of prostate cancer
9. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
10. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
11. Pesticide combinations imperil frogs, probably contribute to amphibian decline

Post Your Comments:
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
(Date:6/25/2015)... 2015 Research ... the addition of the  "2015 Market ... Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, ... Labs, POC Locations"  report to ... http://photos.prnewswire.com/prnh/20130307/600769) , A new ...
(Date:6/25/2015)... ... June 25, 2015 , ... The American Brain Tumor ... Patient and Family Conference, Providing and Pursuing Answers: Advances in Research, Treatment and ... Suites Hotel, July 24-25, 2015. , “As advances in research accelerate the arrival ...
(Date:6/25/2015)... SAN DIEGO , June 25, 2015  BioMed ... that Illumina, Inc. (NASDAQ: ILMN ), a world ... unlocking the power of the genome, has signed a ... innovative scientific research building in Cambridge, England ... environment and access to the highly skilled workforce in ...
(Date:6/25/2015)... , June 25, 2015 ... Arzneimittel-Überprüfungs- und -Authentifizierungsdienstleistungen, führte am 24. und ... am Main das 2. Eco ... Informations-Veranstaltung zum Thema Sicherheit für Patienten in ...      (Logo: http://photos.prnewswire.com/prnh/20150610/748687) , ...
Breaking Biology Technology:Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3Nationally Recognized Brain Tumor Experts to Speak at American Brain Tumor Association Patient and Family Conference 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 3Symposium zur Richtlinie über gefälschte Arzneimittel - mit Aegate in Deutschland 2Symposium zur Richtlinie über gefälschte Arzneimittel - mit Aegate in Deutschland 3
Cached News: